Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.
about
Challenges in the clinical measurement of ocular surface disease in glaucoma patients.Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapyInitial Treatment: Prostaglandin Analog or Selective Laser TrabeculoplastyTherapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma MedicationsHow ocular surface disease impacts the glaucoma treatment outcomeBenzalkonium chloride and glaucoma.Ophthalmic preservatives: focus on polyquaternium-1.Overview of the [corrected] travoprost /timolol BAK-free fixed combination.Latanoprost/timolol fixed combination for the treatment of glaucoma.Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?Prostaglandin analogues in angle closure glaucoma.Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment.Glaucoma therapy: preservative-free for all?
P2860
Q35555771-88995398-3367-4644-9147-8B602586B129Q35596464-BD4C187A-5271-43C6-A708-BEF89A7ADBCDQ35964378-7CE58694-A166-4307-A386-A6E745BB0D2AQ36498525-DB596B65-AFAE-4AE3-BB97-4E7D7CCA135CQ37259818-B2602E1B-886D-4D6A-9F08-7B36EC67156BQ37710684-45C8EA48-D816-4F14-B711-063B88E3F9EFQ37929746-2EE9E6F2-266D-4B9D-9B0B-63867A4A8402Q37987586-D950E49F-8FEF-4B2E-A9A4-09D0D57060FFQ38117401-7CA9FD09-F381-49CE-83ED-200E9010CE55Q38843414-9A00D639-EE00-4743-BD9C-B0D010C36158Q42040480-AB12AC6D-0BA3-4C40-BF16-9183EF929470Q42872364-8CD364CB-3524-448F-B741-A32A81FF67C0Q44649981-094448E1-C9B1-4161-9362-3FB673C50B1BQ47170651-9F84CE9B-6A26-425B-A364-9BC670BE31D1Q55101249-6BB3970A-5D3E-48B7-92E0-C959D4095BC3
P2860
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@ast
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@en
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@nl
type
label
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@ast
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@en
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@nl
prefLabel
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@ast
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@en
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@nl
P2093
P2860
P356
P1476
Ocular surface disease in pati ...... oprost or BAK-free travoprost.
@en
P2093
Clark L Springs
E Randy Craven
Gregory Katz
Michela Montecchi-Palmer
P2860
P304
P356
10.2147/OPTH.S14113
P407
P577
2010-11-03T00:00:00Z